Targets › CD56
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: the race on CD56, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Biotech | EB-DART-NK01 Allogeneic dual-target CAR-NK cells (DLL3/CD56, DLL3/GD2, or CD56/GD2) | DLL3, CD56, GD2 | Phase 1 | Small Cell Lung Cancer (SCLC) | Feb 2027 |
Small Cell Lung Cancer (SCLC) (2)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.